Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 13/20 | 0.65 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.45 |
| ▸ | INCENP | Q9NQS7 | 3/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29963339 | 1.00 | SYK (0.65) | SYKFFAR1HRH1AURKBINCENP | |
| SCHEMBL29195674 | 0.82 | CCR5 (0.51) | SYKFFAR1AURKBINCENPABCB1 | |
| SCHEMBL21801177 | 0.82 | SYK (0.65) | SYKHRH1AURKBINCENPABCB1 | |
| SCHEMBL159323 | 0.82 | SYK (0.78) | SYKAURKBINCENPABCB1HTR1A | |
| SCHEMBL1406302 | 0.82 | SYK (0.69) | SYKAURKBINCENPABCB1HTR1A | |
| SCHEMBL30354925 | 0.82 | SYK (0.69) | SYKAURKBINCENPABCB1HTR1A | |
| SCHEMBL8306570 | 0.82 | SYK (0.54) | SYKFFAR1HRH1AURKBINCENP | |
| SCHEMBL29638125 | 0.82 | SYK (0.78) | SYKAURKBINCENPABCB1HTR1A | |
| SCHEMBL30686435 | 0.82 | SLC6A4 (0.57) | SYKFFAR1AURKBINCENPABCB1 | |
| SCHEMBL1406446 | 0.82 | SYK (0.65) | SYKAURKBINCENPABCB1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246934-A1 | QUINAZOLINE-BASED COMPOUND, COMPOSITION, AND APPLICATION OF QUINAZOLINE-BASED COMPOUND | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2024-07-25 | — | — | US | disclosed |
| EP-4293016-A1 | QUINAZOLINE-BASED COMPOUND, COMPOSITION, AND APPLICATION OF QUINAZOLINE-BASED COMPOUND | Beijing Scitech-MQ Pharmaceuticals Limited (CN) | 2023-12-20 | — | — | EP | disclosed |
| WO-2020205627-A1 | USE OF BIOMARKER IN CANCER THERAPY | RAIN THERAPEUTICS INC. (US) | 2020-10-08 | — | — | WO | disclosed |
| US-7081461-B1 | Quinazoline compounds and pharmaceutical compositions containing them | ASTRAZENECA AB (SE) | 2006-07-25 | — | — | US | disclosed |
| EP-1218356-A1 | QUINAZOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AstraZeneca AB (SE) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001021594-A1 | QUINAZOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 2001-03-29 | — | — | WO | disclosed |
| EP-0790986-B1 | ANILINE DERIVATIVES | ZENECA LTD (GB) | 1999-01-20 | — | — | EP | disclosed |
| US-5821246-A | USEFUL AS TYROSINE KINASE INHIBITORS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | ZENECA LIMITED (GB) | 1998-10-13 | — | — | US | disclosed |
| EP-0790986-A1 | ANILINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-08-27 | — | — | EP | disclosed |
| WO-1996015118-A1 | ANILINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246934-A1 | QUINAZOLINE-BASED COMPOUND, COMPOSITION, AND APPLICATION OF QUINAZOLINE-BASED COMPOUND | ABL1, ERBB2, EGFR | SYK 678/4885FFAR1 3888/4885HRH1 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.